Doctoral Thesis Defenses 2020:

1. Sophie Berends, January 2020: Anti-TNF therapy in inflammatory bowel disease: towards personalized medicine (promotors G D’Haens and R Mathot, co-promotors…)

2. Felicia Bloemendaal, July 2020: Macrophages as a therapeutic target in inflammatory bowel disease: lessons learned from anti-TNF therapy (promotors G vanden Brink and G D’Haens, copromotors…)

3. Merle Stellingwerf: (promotors W Bemelman and G D’Haens, copromotors C Buskens and …)

4. Leonie C.S. de Vries, November 2020: Janus kinase inhibition in the treatment of Inflammatory Bowel Disease (promotors W de Jonge and G D’Haens, copromotors M Wildenberg and …)

Doctoral Thesis Defenses 2021:

Immunogenicity of the currently recommended pneumococcal vaccination schedule in patients with inflammatory bowel disease. van Aalst M, Garrido HMG, van der Leun J, Meek B, van Leeuwen EMM, Löwenberg M, D’Haens GR, Ponsioen CYI, Grobusch MP, Goorhuis A.
Clin Infect Dis. 2020;70:595-604.

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease.Dreesen E, Baert F, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Oldenburg B, Pariente B, Pierik M, van der Woude CJ, D’Haens G, Vermeire S, Gils A. Clin Gastroenterol Hepatol. 2020;18:637-646.

Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Panaccione R, Colombel JF, Travis SPL, Bossuyt P, Baert F, Vaňásek T, Danalıoğlu A, Novacek G, Armuzzi A, Reinisch W, Johnson S, Buessing M, Neimark E, Petersson J, Lee WJ, D’Haens GR. Gut 2020;69:658-664.

IBD-Associated Dysplastic Lesions Show More Chromosomal Instability Than Sporadic Adenomas. Wanders LK, Cordes M, Voorham Q, Sie D, de Vries SD, D’Haens GRAM, de Boer NKH, Ylstra B, van Grieken NCT, Meijer GA, Dekker E, Carvalho B. Inflamm Bowel Dis. 2020; 26:167-180.

Response to Placebo, Measured by Endoscopic Evaluation of Crohn’s Disease Activity, in a Pooled Analysis of Data from 5 Randomized Controlled Induction Trials. Duijvestein M, Jeyarajah J, Guizzetti L, Zou G, Parker CE, van Viegen T, VandeCasteele N, Khanna R, Van Der Aa A, Sandborn WJ, Feagan BG, D’Haens GR, Jairath V. Clin Gastroenterol Hepatol. 2020;18:1121-1132.

Complications while waiting for IBD surgery- short report. Wasmann KA; IBD study group Amsterdam UMC, location AMC . J Crohns Colitis. 2020; 14:277-280.

Reliability of Endoscopic Evaluation of Postoperative Recurrent Crohn’s Disease. Ma C, Gecse KB, Duijvestein M, Sandborn WJ, Zou G, Shackleton LM, Stitt LW, Parker CE, Bossuyt P, Löwenberg M, Khanna R, Vermeire S, Rutgeerts P, Feagan BG, Jairath V, D’Haens GR. Clin Gastroenterol Hepatol. 2020;18:2139-2141.

Monitoring of Adalimumab Concentrations at Home in Patients with Inflammatory Bowel Disease using Dried Blood Samples. Berends SE, Bloem K, de Vries A, Schaap T, Rispens T, Strik AS, Talwar R, Löwenberg M, D’Haens GR, Mathôt RA. Ther Drug Monit. 2020;42:289-294.

Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling. Koelink PJ, Bloemendaal FM, Li B, Westera L, Vogels EWM, van Roest M, Gloudemans AK, van ’t Wout AB, Korf H, Vermeire S, Te Velde AA, Ponsioen CY, D’Haens GR, Verbeek JS, Geiger TL, Wildenberg ME, van den Brink GR. Gut 2020; 69:1053-1063.

A prospective study comparing patient-reported outcomes in Crohn’s disease. Hoekman DR, Löwenberg M, van den Brink GR, Ponsioen CY, Benninga MA, D’Haens GR. Eur J Gastroenterol Hepatol. 2020;32:38-44.

Development and validation of a test to monitor endoscopic activity in patients with Crohn’s disease based on serum levels of proteins. D’Haens G, Kelly O, Battat R, Silverberg MS, Laharie D, Louis E, Savarino E, Bodini G, Yarur A, Boland BS, Afif W, Li XJ, Hale M, Ho J, Kondragunta V, Huang B, Kuy C, Okada L, Hester KD, Bray KR, Mimms L, Jain A, Singh S, Collins A, Valasek MA, Sandborn WJ, Vermeire S, Dulai PS. Gastroenterology 2020;158:515-526.

Anti-interleukin-23 agents for the treatment of ulcerative colitis. Hanžel J, D’Haens GR. Expert Opin Biol Ther.2020;20:399-406.

Bowel ultrasound measurements in healthy children – systematic review and meta-analysis. van Wassenaer EA, de Voogd FAE, van Rijn RR, van der Lee JH, Tabbers MM, van Etten-Jamaludin FS, Kindermann A, de Meij TGJ, Gecse KB, D’Haens GR, Benninga MA, Koot BGP. Pediatr Radiol. 2020; 50:501-508.

Systematic review and external validation of prediction models based on symptoms and biomarkers for identifying endoscopic activity in Crohn’s disease. Brand EC, Elias SG, Minderhoud IM, van der Veen JJ, Baert FJ, Laharie D, Bossuyt P, Bouhnik Y, Buisson A, Lambrecht G, Louis E, Pariente B, Pierik MJ, van der Woude CJ, D’Haens GRAM, Vermeire S, Oldenburg B; Dutch Initiative on Crohn and Colitis (ICC). Clin Gastroenterol Hepatol. 2020; 18: 1704-1718.

Treatment of perianal fistulas in Crohn’s disease, seton versus anti-TNF versus surgical closure following anti-TNF (PISA): a randomised controlled trial. Wasmann KATGM, de Groof EJ, Stellingwerf ME, D’Haens GR, Ponsioen CY, Gecse KB, Dijkgraaf MGW, Gerhards MF, Jansen JM, Pronk A, van Tuyl SAC, Zimmerman DDE, Bruin KF, Spinelli A, Danese S, van der Bilt JDW, Mundt MW, Bemelman WA, Buskens CJ. J Crohns Colitis. 2020;14:1049-1056.

Deep Remission at 1Year Prevents Progression of Early Crohn’s Disease. Ungaro RC, Yzet C, Bossuyt P, Baert FJ, Vanasek T, D’Haens GR, Joustra VW, Panaccione R, Novacek G, Reinisch W, Armuzzi A, Golovchenko O, Prymak O, Goldis A, Travis SP, Hébuterne X, Ferrante M, Rogler G, Fumery M, Danese S, Rydzewska G, Pariente B, Hertervig E, Stanciu C, Serrero M, Diculescu M, Peyrin-Biroulet L, Laharie D, Wright JP, Gomollón F, Gubonina I, Schreiber S, Motoya S, Hellström PM, Halfvarson J, Butler JW, Petersson J, Petralia F, Colombel JF. Gastroenterology 2020;159:139-147.

Whole-Genome DNA Methylation Profiling of CD14+ Monocytes Reveals Disease Status and Activity Differences in Crohn’s Disease Patients. Li Yim AYF, Duijvis NW, Ghiboub M, Sharp C, Ferrero E, Mannens MMAM, D’Haens GR, de Jonge WJ, Te Velde AA, Henneman P. J Clin Med. 2020;9:1055.

Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease. Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-Collet C, Pariente B, Filippi J, Baert F, D’Haens G, Laharie D, Peyrin-Biroulet L, Vermeire S; Tailorix study group. Clin Gastroenterol Hepatol. 2020 Apr 28. pii: S1542-3565(20)30597-8. doi: 10.1016/j.cgh.2020.04.052. [Epub ahead of print]

High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. van Gennep S, Evers SW, Rietdijk ST, Gielen ME, de Boer NKH, Gecse KB, Ponsioen CIJ, Duijvestein M, D’Haens GR, de Boer AGEM, Löwenberg M. Inflamm Bowel Dis. 2020 May 7. pii: izaa082. doi: 10.1093/ibd/izaa082. [Epub ahead of print]

High-dose Vitamin D does not prevent postoperative recurrence of Crohn’s disese in a randmomized placebo-controlled trial. de Bruyn JR, Bossuyt P, Ferrante M, West RL, Dijkstra G, Witteman BJ, Wildenberg M, Hoentjen F, Franchimont D, Clasquin E, van der Bilt JD, Tollens T, Bemelman WA, D’Hoore A, Duijvestein M, D’Haens GR; Dutch-Belgian DETECT study group. Clin Gastroenterol Hepatol. 2020 May 24:S1542-3565(20)30698-4. doi: 10.1016/j.cgh.2020.05.037. Online ahead of print.

Off-label use of hyperbaric oxygen therapy in inflammatory bowel disease. Lansdorp CA, Buskens CJ, Gecse KB, D’Haens GRAM, van Hulst RA. Aliment Pharmacol Ther. 2020;52:215-216.

A nationwide database study on colectomy and colorectal cancer in ulcerative colitis: what is the role of appendectomy? Stellingwerf ME, Bemelman WA, Löwenberg M, Ponsioen CY, D’Haens GR, van Dieren S, Buskens CJ; Parelsnoer Institute (PSI) and the Dutch Initiative on Crohn and Colitis (ICC). Colorectal Dis. 2020 Jun 10. doi: 10.1111/codi.15184. Online ahead of print.

Safety of Rapid Infliximab Infusions in Children: A Systematic Review. van Wassenaer EA, van Oosterhout JPM, Daams JG, van den Berg MJM, van der Lee H, D’Haens GR, de Meij TGJ, Benninga MA, Koot BGP.J Pediatr Gastroenterol Nutr. 2020 Jun 15. doi: 10.1097/MPG.0000000000002815. Online ahead of print.PMID: 32558671

Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn’s disease. Dreesen E, Berends S, Laharie D, D’Haens G, Vermeire S, Gils A, Mathôt R.

Wound healing of metastatic perineal Crohn’s disease using hyperbaric oxygen therapy: A case series. Lansdorp CA, Buskens CJ, Gecse KB, D’Haens GR, Van Hulst RA.United European Gastroenterol J. 2020 Jun 12:2050640620934915. doi: 10.1177/2050640620934915. Online ahead of print.PMID: 32529922.

Systematic Review: Histological Scoring of Strictures in Crohn’s Disease. De Voogd FA, Mookhoek A, Gecse KB, De Hertogh G, Bemelman WA, Buskens CJ, D’Haens GR. J Crohns Colitis. 2020;14:734-742.

Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Stevens TW, Haasnoot ML, D’Haens GR, Buskens CJ, de Groof EJ, Eshuis EJ, Gardenbroek TJ, Mol B, Stokkers PCF, Bemelman WA, Ponsioen CY; LIR!C study group. Lancet Gastroenterol Hepatol. 2020;5:900-907.

How to Manage Crohn’s Disease After Ileocolonic Resection? Tilg H, D’Haens G. Gastroenterology 2020; 159:816-820.

Diagnostic Accuracy of Fecal Calprotectin Concentration in Evaluating Therapeutic Outcomes of Patients With Ulcerative Colitis. Stevens TW, Gecse K, Turner JR, de Hertogh G, Rubin DT, D’Haens GR. Clin Gastroenterol Hepatol. 2020 Aug 13:S1542-3565(20)31128-9. doi: 10.1016/j.cgh.2020.08.019. Online ahead of print.

Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring? Argollo M, Kotze PG, Kakkadasam P, D’Haens G. Nat Rev Gastroenterol Hepatol. 2020;17:702-710.

Tyrosine kinase 2 signalling drives pathogenic T-cells in colitis. De Vries LCS, Ghiboub M, van Hamersveld PHP, Welting O, Verseijden C, Bell MJ, Rioja I, Prinjha RK, Koelink PJ, Strobl B, Müller M, D’Haens GR, Wildenberg ME, De Jonge WJ.J Crohns Colitis. 2020 Oct 1:jjaa199. doi: 10.1093/ecco-jcc/jjaa199. Online ahead of print.

Impaired Quality of Working Life in Inflammatory Bowel Disease Patients. van Gennep S, de Boer NKH, Gielen ME, Rietdijk ST, Gecse KB, Ponsioen CY, Duijvestein M, D’Haens GR, Löwenberg M, de Boer AGEM. Dig Dis Sci. 2020 Oct 16. doi: 10.1007/s10620-020-06647-y. Online ahead of print.

Can 2 Different Fecal Calprotectin Assays be Used Interchangeably in IBD Treatment? van Wassenaer EA, Diederen K, van Leeuwen EMM, D’Haens GR, Benninga MA, Koot BGP, Kindermann A.J Clin Gastroenterol. 2020 Oct 27. doi: 10.1097/MCG.0000000000001460. Online ahead of print.PMID: 33116067

Hypnotherapy for irritable bowel syndrome-type symptoms in patients with quiescent inflammatory bowel disease: a randomized, controlled trial. Hoekman DR, Vlieger AM, Stokkers PC, Mahhmod N, Rietdijk S, de Boer NK, de Meij TG, Frankenhuis C, D’Haens GR, Benninga MA. J Crohns Colitis. 2020 Nov 27:jjaa241. doi: 10.1093/ecco-jcc/jjaa241. Online ahead of print.